vs
Side-by-side financial comparison of FULTON FINANCIAL CORP (FULT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $336.2M, roughly 1.9× FULTON FINANCIAL CORP). Royalty Pharma plc runs the higher net margin — 34.4% vs 28.2%, a 6.2% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 4.2%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 0.2%).
Fulton Financial Corporation is an American regional financial services holding company, headquartered in Lancaster, Pennsylvania.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
FULT vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $336.2M | $622.0M |
| Net Profit | $94.8M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | — | 62.4% |
| Net Margin | 28.2% | 34.4% |
| Revenue YoY | 4.2% | 4.8% |
| Net Profit YoY | 1.9% | 2.9% |
| EPS (diluted) | $0.55 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $336.2M | — | ||
| Q4 25 | $336.0M | $622.0M | ||
| Q3 25 | $334.6M | $609.3M | ||
| Q2 25 | $324.1M | $578.7M | ||
| Q1 25 | $318.4M | $568.2M | ||
| Q4 24 | $319.6M | $593.6M | ||
| Q3 24 | $317.7M | $564.7M | ||
| Q2 24 | $334.7M | $537.3M |
| Q1 26 | $94.8M | — | ||
| Q4 25 | $99.0M | $214.2M | ||
| Q3 25 | $100.5M | $288.2M | ||
| Q2 25 | $99.2M | $30.2M | ||
| Q1 25 | $93.0M | $238.3M | ||
| Q4 24 | $68.6M | $208.2M | ||
| Q3 24 | $63.2M | $544.0M | ||
| Q2 24 | $95.0M | $102.0M |
| Q1 26 | — | — | ||
| Q4 25 | 35.7% | 62.4% | ||
| Q3 25 | 38.2% | 70.1% | ||
| Q2 25 | 37.8% | 36.3% | ||
| Q1 25 | 36.1% | 94.0% | ||
| Q4 24 | 27.0% | 60.9% | ||
| Q3 24 | 25.1% | — | ||
| Q2 24 | 30.8% | 50.2% |
| Q1 26 | 28.2% | — | ||
| Q4 25 | 29.5% | 34.4% | ||
| Q3 25 | 30.0% | 47.3% | ||
| Q2 25 | 30.6% | 5.2% | ||
| Q1 25 | 29.2% | 41.9% | ||
| Q4 24 | 21.5% | 35.1% | ||
| Q3 24 | 19.9% | 96.3% | ||
| Q2 24 | 28.4% | 19.0% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.53 | $0.49 | ||
| Q3 25 | $0.53 | $0.67 | ||
| Q2 25 | $0.53 | $0.07 | ||
| Q1 25 | $0.49 | $0.55 | ||
| Q4 24 | $0.36 | $0.46 | ||
| Q3 24 | $0.33 | $1.21 | ||
| Q2 24 | $0.52 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $3.5B | $9.7B |
| Total Assets | $32.2B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | $9.7B | ||
| Q3 25 | $3.4B | $9.6B | ||
| Q2 25 | $3.3B | $9.5B | ||
| Q1 25 | $3.3B | $9.8B | ||
| Q4 24 | $3.2B | $10.3B | ||
| Q3 24 | $3.2B | $10.3B | ||
| Q2 24 | $3.1B | $9.8B |
| Q1 26 | $32.2B | — | ||
| Q4 25 | $32.1B | $19.6B | ||
| Q3 25 | $32.0B | $19.3B | ||
| Q2 25 | $32.0B | $18.3B | ||
| Q1 25 | $32.1B | $17.6B | ||
| Q4 24 | $32.1B | $18.2B | ||
| Q3 24 | $32.2B | $18.0B | ||
| Q2 24 | $31.8B | $17.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $304.5M | $827.1M | ||
| Q3 25 | $116.1M | $702.6M | ||
| Q2 25 | $91.7M | $364.0M | ||
| Q1 25 | $703.0K | $596.1M | ||
| Q4 24 | $416.6M | $742.5M | ||
| Q3 24 | $-22.0M | $703.6M | ||
| Q2 24 | $157.8M | $658.2M |
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | 3.86× | ||
| Q3 25 | 1.16× | 2.44× | ||
| Q2 25 | 0.92× | 12.06× | ||
| Q1 25 | 0.01× | 2.50× | ||
| Q4 24 | 6.07× | 3.57× | ||
| Q3 24 | -0.35× | 1.29× | ||
| Q2 24 | 1.66× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FULT
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
